Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837549 | 0.93 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL6838571 | 0.82 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2BMAPT | |
| SCHEMBL6425210 | 0.81 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL6424993 | 0.81 | ADORA2A (0.54) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6838587 | 0.77 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL2912457 | 0.76 | ADORA2A (0.54) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6378406 | 0.75 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL6840000 | 0.73 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6838033 | 0.71 | ADORA2A (0.44) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL13787683 | 0.70 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADORA3 170/4885ALDH1A1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.